Axel Hauschild
机构: Professor of Dermatology, University Hospital Kiel, Germany
主页: uni-kiel.de
每年引用次数
引用次数
引用: 77,792
H-指数: 114
I10-指数 : 404
出版物: 1,086
Long Georgina V, Flaherty Keith, Nathan Paul, Ribas Antoni, Martin Anne-Marie, Sun Peng, Crist Wendy, Legos Jeff, Rubin Stephen D, Little Shonda M, Schadendorf Dirk. Improved overall survival in melanoma with combined dabrafenib and trametinib
Robert Caroline , Karaszewska Boguslawa , Schachter Jacob , Rutkowski Piotr
The New England journal of medicine 372 30 -39
5
2015
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
Garbe Claus , Peris Ketty , Hauschild Axel , Saiag Philippe
Eur J Cancer 46 ( 2) 270 -83
6
2010
Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial
Lebbe C , Garbe C , Schadendorf D , Testori A
In: International Melanoma Congress 'Pathology Symposium & Primary Care Update'; 10 Nov 2011-14 Nov 2011; Tampa, Florida. JCO; 2011.
9
2011
Malignant melanoma in adolescents
Hauschild A , Christophers E
Deutsche Medizinische Wochenschrift 120 ( 42) 1452
1
1995
[Intralesional treatment of classical Kaposi sarcoma with interferon-alpha].
Hauschild A , Petres-Dunsche C
Hautarzt 43 ( 12) 789 -791
15
1992
Cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V
Hauschild A , Garbe C
Hautarzt
2
1998
[Formalin-resistant leukocyte differentiation antigens in dermatohistopathology].
Hauschild A , Sterry W
Hautarzt 41 ( 7) 345 -352
1990
[Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group].
Tilgen W , Garbe C , Schadendorf D , Dummer R
Hautarzt 49 ( 3) 167
2
1998
Lipoma of the lip. A rare differential diagnosis
Rosien F , Lischner S , Haacke Tc , Hauschild A
Hautarzt 53 ( 6) 400 -402
2002
Formalin-resistant leukocyte surface antigens in the diagnosis of cutaneous malignant lymphomas.
A. Hauschild , W. Sterry
American Journal of Pathology 135 ( 1) 177 -184
8
1989
Therapie des Merkel-Zell-Karzinoms
A. Hauschild , E. Christophers
Zeitschrift für Hautkrankheiten 72 ( 1) 15 -18
2
1997
Adjuvante systemische Therapie des Melanoms
F. Egberts , A. Hauschild , P. Mohr , K. C. Kähler
Hautarzt 62 ( 6)
2011
Morbidity after radical Lymphadenectomy for Melanoma patients: Influence of the POSSUM Score and a previous Sentinel lymph node removal
C. Hartje , C. Schafmayer , J. H. Egberts , K. C. Kaehler
Egberts, F., Hartje, C., Kaehler, K. C., Schafmayer, C., Hauschild, A. and Egberts, J. H. (2011) Morbidity after radical Lymphadenectomy for Melanoma patients: Influence of the POSSUM Score and a previous Sentinel lymph node removal Journal Der Deutschen Dermatologischen Gesellschaft, 9 . p. 228.
2011
Cutaneous Side Effects of combination Therapy with Sorafenib and Peginterferon - an Evaluation of the SoraPeg Study of the ADO
C. Garbe , F. Egberts , M. Weichenthal , R. Gutzmer
Degen, A., Weichenthal, M., Ugurel, S., Trefzer, U., Gauwerky, K., Garbe, C., Egberts, F., Frey, L., Hauschild, A. and Gutzmer, R. (2011) Cutaneous Side Effects of combination Therapy with Sorafenib and Peginterferon - an Evaluation of the SoraPeg Study of the ADO Journal Der Deutschen Dermatologischen Gesellschaft, 9 (9). p. 779.
2011
Neo-adjuvant Therapy of Dermatofibrosarcoma protuberans with Imatinib: A multicenter Phase II Study of the ADO
P. Helmbold , M. Leverkus , D. Schadendorf , J. Utikal
Journal Der Deutschen Dermatologischen Gesellschaft 11 ( 9)
2013
Nanoemulsion aminolaevulinic acid photodynamic therapy for nonaggressive basal cell carcinoma: a comparison study
S. Ibbotson , T. Dirschka , U. Reinhold , C. Berking
British Journal of Dermatology
2017
BF‐200 ALA凝胶与MAL乳膏治疗BCC的对比
H. Lübbert , S. Ibbotson , T. Dirschka , U. Reinhold
British Journal of Dermatology 179 ( 2)
2018
BF‐200 ALA gel vs. MAL cream for BCC
H. Lübbert , S. Ibbotson , T. Dirschka , U. Reinhold
British Journal of Dermatology 179 ( 2)
2018
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (ASCO 2011 Melanoma, Abstract LBA4)
C. Garbe , A. Testori , K. B. Nolop , P. Lorigan
ASCO
2011
Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real world conditions in Germany - the non-interventional study NIELS.
D. Schadendorf , R. Gutzmer , S. Haferkamp , U. Leiter
Journal of The European Academy of Dermatology and Venereology
2021